Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
36.12 USD | +0.35% | +28.22% | +75.20% |
12:52pm | Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target | MT |
May. 24 | Mizuho Securities Starts Cartesian Therapeutics With Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.20% | 641M | |
+15.85% | 121B | |
+13.72% | 107B | |
-3.35% | 24.82B | |
+1.83% | 22.48B | |
-9.70% | 18.32B | |
-42.28% | 16.33B | |
-16.18% | 15.31B | |
+4.77% | 14.08B | |
+27.10% | 11.74B |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Transcript : Selecta Biosciences, Inc., Q2 2023 Earnings Call, Aug 17, 2023